Vectura Group Share Price (VEC)

170.00 0.00 (0.00%) delayed: 3:48AM GMT
Bid price 169.90 Open price 171.00
Ask price 170.30 Prev close 170.00
High price 172.00 Spread 0.23%
Low price 168.20 Volume 308,869

Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.

Vectura Group Share Price Chart

Advanced Charts >>

Register now for FREE Vectura Group share price charts

Vectura Group Share Price Information

Name Vectura Group Epic VEC
Sector Pharmaceuticals & Biotechnology ISIN GB00B01D1K48
Activites Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. Index FTSE 250

Vectura Group Key Numbers

Latest Share Price (p) 170.00 Net Gearing (%) -6.27
Market Capitalisation (£m) 687.68 Gross Gearing (%) 24.40
Shares in issue (m) 404.52 Debt Ratio 10.20
P/E Ratio 188.89 Debt-to-Equity Ratio 0.35
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.32
Dividend Yield (%) 0.00 Price to book value 3.10
Dividend cover (x) 0.00 ROCE (%) -2.51
Earning per share (p) 0.90 EPS Growth (%) 228.57
52 week high / low 187.50 / 121.50 DPS Growth (%) n/a

Vectura Group Director Deals

Dec.Date Type Director Pos No. of Shares
05/10/2015 TIN Dr Trevor Phillips ED 205,329
07/07/2015 BUY Dr Trevor Phillips ED 1,000
07/07/2015 BUY Andrew Oakley FD 1,000
17/04/2015 EXR Dr Christopher Blackwell RES 18,987
16/01/2015 EXR Dr Trevor Phillips ED 3,133

More Vectura Group Director Deals >>

Vectura Group Company News

07:51 17/11/2015

Vectura narrows H1 pretax loss on royalties spike

Vectura has narrowed its H1 pretax loss to GBP5.0m, from a loss of GBP8.7m, as royalties spiked 67% higher. "Vectura is continuing to make very good progress with robust financial performance reflecting good pipeline progress and significant increases in partnered product sales," said CEO James...

07:13 17/11/2015

FLASH: Vectura narrows H1 pretax loss on royalties spike

Story provided by

07:02 17/11/2015

Study shows Novartis Ultibro Superior to Seretide

/* */ RNS Number : 8923F Vectura Group plc 17 November 2015   Vectura Group plc FLAME study shows superiority of Novartis' Ultibro ® Breezhaler ® over Seretide ® in reducing COPD exacerbations   ·     ...

More Vectura Group Company News >>

Register now for FREE Vectura Group company news

Vectura Group Share Price Discussions

8 months ago


Powered by IST's

Register now for FREE Vectura Group share price discussions